Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers

Blood

Volumn 117, Issue 3, 2011, Pages 902-914

  Pillozzi, Serena ^a   Masselli, Marika ^a   De Lorenzo, Emanuele ^a   Accordi, Benedetta ^b   Cilia, Emanuele ^a   Crociani, Olivia ^a   Amedei, Amedeo ^a   Veltroni, Marinella ^b   D'Amico, Massimo ^a   Basso, Giuseppe ^b   Becchetti, Andrea ^c   Campana, Dario ^d   Arcangeli, Annarosa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; BETA1 INTEGRIN; CHEMOKINE RECEPTOR CXCR4; DEXAMETHASONE; DOXORUBICIN; ERYTHROMYCIN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N METHYL N [2 [METHYL(1 METHYL 1H BENZIMIDAZOL 2 YL)AMINO]ETHYL] 4 [(METHYLSULFONYL)AMINO]BENZENESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL HERG1; PREDNISONE; ROSCOVITINE; SERTINDOLE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER INVASION; CELL MEMBRANE; CELL SURVIVAL; COCULTURE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 78751689287     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-262691     Document Type: Article

References (50)

1. Pui CH, Campana D, Pei D, et al. Treatment of childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730-2741.
2. Mullighan CG, Su X, Zhang J, et al; Children's Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-480.
3. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147-156.
4. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-178.
5. Konopleva M, Konoplev S, Hu W. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002;16(9):1713-1724.
6. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1996;92(1):97-103. (Pubitemid 26018774)
7. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood. 1998;91(7):2387-2396. (Pubitemid 28155513)
8. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96(8):2655-2663.
9. Weisberg E, Wright RD, McMillin DW, et al. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther. 2008;7(5):1121-1129.
10. Manabe A, Murti KG, Coustan-Smith E, et al. Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood. 1994;83(3):758-766. (Pubitemid 24043737)
11. Kumagai M, Manabe A, Pui CH, et al. Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest. 1996;97(3):755-760. (Pubitemid 26057095)
12. Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest. 2007;117(4):1049-1057. (Pubitemid 46556761)
13. Mudry RE, Fortney JE, York T, Hall BM, Gibson LF. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood. 200;96(5):1926-1932.
14. Zeng Z, Samudio IJ, Munsell M, et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol. Cancer Ther. 2006;5(12):3113-3121. (Pubitemid 46092053)
15. Nakata Y, Tomkowicz B, Gewirtz AM, Ptasznik A. Integrin inhibition through Lyn-dependent cross talk from CXCR4 chemokine receptors in normal human CD34+ marrow cells. Blood. 2006;107(11):4234-4239. (Pubitemid 43801345)
16. Tabe Y, Jin L, Tsutsumi-Ishii Y, et al. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res. 2007;67(2):684-694. (Pubitemid 46192208)
17. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene. 2005;24(27):4462-4471. (Pubitemid 40961769)
18. Jin L, Tabe Y, Konoplev S, et al. CXCR4 upregulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther. 2008;7(1):48-58.
19. Streuli CH, Akhtar N. Signal co-operation between integrins and other receptor systems. Biochem J. 2009;418(3):491-506.
20. Arcangeli A, Becchetti A. Complex functional interaction between integrin receptors and ion channels. Trends Cell Biol. 2006;16(12):631-639. (Pubitemid 44809885)
21. Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S, Becchetti A. Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr Med Chem. 2009;16(1):66-93.
22. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440(7083):463-469.
23. Arcangeli A. Expression and role of hERG channels in cancer cells. Novartis Found Symp. 2005;266:225-232.
24. Pillozzi S, Arcangeli A. Physical and functional interaction between integrins and hERG1 channels in cancer cells. Adv Exp Med Biol. 2010;674:55-67.
25. Rosenfeld C, Goutner A, Choquet C, et al. Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line. Nature. 1977;267(5614):841-843. (Pubitemid 8110160)
26. Findley HW, Cooper MD, Findley HW, et al. Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes. Blood. 1982;60(6):1305-1309.
27. Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood. 1985;65(1):21-31.
28. Mihara K, Imai C, Coustan-Smith E, et al. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol. 2003;120(5):846-849. (Pubitemid 36315109)
29. Pillozzi S, Brizzi MF, Bernabei PA, et al. VEGFR-1 (FLT-1), beta-1 integrin and hERG K+ channel form a macromolecular signalling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood. 2007;110(4):1238-1250. (Pubitemid 47281422)
30. Schönherr R, Rosati B, Hehl S, et al. Functional role of the slow activation property of ERG K+ channels. Eur J Neurosci. 1999;11(3):753-760.
31. Hara J, Matsuda Y, Fujisaki H, et al. Expression of adhesion molecules in childhood B-lineage-cell neoplasms. Int J Hematol. 2000;72(1):69-73.
32. Dürig J, Schmücker U, Dührsen U. Differential expression of chemokine receptors in B cell malignancies. Leukemia. 2001;15(5):752-756. (Pubitemid 32492698)
33. Bianchi L, Wible B, Arcangeli A, et al. herg encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Res. 1998;58(4):815-822. (Pubitemid 28099497)
34. Cherubini A, Hofmann G, Pillozzi S, et al. Human ether-a-go-go-related gene 1 channels are physically linked to beta1 integrins and modulate adhesion-dependent signaling. Mol Biol Cell. 2005;16(6):2972-2983. (Pubitemid 40741240)
35. Bradstock KF, Makrynikola V, Bianchi A, Shen W, Hewson J, Gottlieb DJ. Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers. Leukemia. 2000;14(5):882-888. (Pubitemid 30235067)
36. Masi A, Becchetti A, Restano-Cassulini R, et al. hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer. 2005;93(7):781-792. (Pubitemid 41486438)
37. Ganapathi SB, Kester M, Elmslie KS. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. Am J Physiol Cell Physiol. 2009;296(4):C701-C710.
38. Raschi E, Vasina V, Poluzzi E, De Ponti F. The hERG K+ channel: target and antitarget strategies in drug development. Pharmacol Res. 2008;57(3):181-195.
39. H. Lundbeck A/S Denmark Web site. http://www.lundbeck.com/products/Our- products/Serdolect/default.asp. Accessed October 2009.
40. Stanat SJ, Carlton CG, Crumb WJ, Agrawal KC, Clarkson CW. Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem. 2003;254(1-2):1-7. (Pubitemid 37483735)
41. Rampe D, Murawsky MK, Grau J, Lewis EW. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp. Ther. 1998;286(2):788-793. (Pubitemid 29003470)
42. Crumb WJ Jr, Ekins S, Sarazan RD, et al. Effects of antipsychotic drugs on I(to), I(Na), I(sus), I(K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res. 2006;23(6):1133-1143.
43. Chen SZ, Jiang M, Zhen YS. HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin. Cancer Chemother Pharmacol. 2005;56(2):212-220. (Pubitemid 40884277)
44. Bachmann PS, Gorman R, Papa RA, et al. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Res. 2007;67(9):4482-4490. (Pubitemid 46815099)
45. Fedyk ER, Ryyan DH, Ritterman I, Springer TA. Maturation decreases responsiveness of human bone marrow B lineage cells to stromal-derived factor 1 (SDF-1). J Leukoc Biol. 1999;66(4):667-673. (Pubitemid 29489895)
46. Honczarenko M, Douglas RS, Mathias C, Lee B, Ratajczak MZ, Silberstein LE. SDF-1 responsiveness does not correlate with CXCR4 expression levels of developing human bone marrow B cells. Blood. 1999;94(9):2990-2998. (Pubitemid 29512702)
47. Zhou M, Gu L, Findley HW, Jiang R, Woods WG. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res. 2003;63(19):6357-6662. (Pubitemid 37255184)
48. Li H, Du YM, Guo L, et al. The role of hERG1 K+ channels and a functional link between hERG1 K+ channels and SDF-1 in acute leukemic cell migration. Exp Cell Res. 2009;315(13):2256-2264.
49. Witchel HJ, Hancox JC. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current. Clin Exp Pharmacol Physiol. 2000;27(10):753-766.
50. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58(1):32-45. (Pubitemid 36351620)